Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pelthos Therapeutics (PTHS) EBITDA Margin (2024 - 2025)

Pelthos Therapeutics has reported EBITDA Margin over the past 2 years, most recently at 72.74% for Q4 2025.

  • Quarterly results put EBITDA Margin at 72.74% for Q4 2025, down 46535.0% from a year ago — trailing twelve months through Dec 2025 was 135.67% (down 720747.0% YoY), and the annual figure for FY2025 was 257.93%, changed.
  • EBITDA Margin for Q4 2025 was 72.74% at Pelthos Therapeutics, up from 207.43% in the prior quarter.
  • Over the last five years, EBITDA Margin for PTHS hit a ceiling of 114068.61% in Q2 2025 and a floor of 50016.61% in Q2 2024.